Icahn School of Medicine at Mount Sinai, Otolaryngology - Head and Neck Surgery
New York, 10029, United States
NCT Number: NCT01358097
The purpose of this study is to investigate the role of the immune system in the response of squamous cell cancers of the head and neck to treatment that includes radiation therapy. Current research demonstrates that several natural immune cells and molecules affect the way the body's immune system interacts with a cancerous growth. Some cancers may be related to infection with a virus, such as the Human Papilloma Virus (HPV). Studying the activity of the immune system in head and neck cancers, especially cancers related to HPV infections, can provide valuable information to better understand the body's interaction with cancer cells.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
New York, 10029, United States
This is a study of the immune response in patients with oropharyngeal cancer who undergo treatment with radiation, chemoradiation, or robotic surgery. Many oropharyngeal cancers are caused by infection with the human Papillomavirus (HPV), and patients with HPV-mediated tumors have much better prognosis and treatment response compared to patients with HPV-negative tumors. The investigators will test the hypothesis that radiation-based therapy of oropharyngeal cancer is associated with activation of the endogenous HPV-specific immune response. In this study the investigators will collect blood at several time points before, during, and after treatment to monitor the immune response in patients with tumors positive and negative for HPV versus normal healthy volunteers.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: at time of enrollment into study (baseline)
Time frame: after 3 weeks of treatment
Time frame: 3 months after completion of treatment
Time frame: 6 months after completion of treatment
Time frame: 1 year after completion of treatment
Time frame: 2 years after completion of treatment
Time frame: 3 years after completion of treatment
Time frame: at time of enrollment into study (baseline)
Time frame: after 3 weeks of treatment
Time frame: 3 months after completion of treatment
Time frame: 6 months after completion of treatment
Time frame: one year after completion of treatment
Time frame: three years after treatment
Time frame: at time of enrollment (baseline)
Time frame: after 3 weeks of treatment
Time frame: 3 months after completion of treatment
Time frame: 6 months after completion of treatment
Time frame: 1 year after completion of treatment
Time frame: after 3 weeks of treatment
Time frame: 3 months after completion of treatment
Time frame: 6 months after completion of treatment
Time frame: 1 year after completion of treatment
Icahn School of Medicine at Mount Sinai
Other
Biomarkers of Immune Function as Predictors of Head and Neck Squamous Cell Carcinoma (HNSCC) in Response to Therapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03422536
Carcinoma, Carcinoma, Squamous Cell
Tucson, Arizona, United States
View Trial DetailsNCT07209189
Carcinoma, Carcinoma, Squamous Cell
Baltimore, Maryland, United States
View Trial DetailsNCT04198766
Adenocarcinoma, Bronchial Neoplasms
Duarte, California, United States
View Trial DetailsNCT03336606
Carcinoma, Carcinoma, Squamous Cell
Portland, Oregon, United States
View Trial Details